NasdaqCM - Delayed Quote USD

Iterum Therapeutics plc (ITRM)

0.9598
-0.0002
(-0.02%)
At close: June 4 at 4:00:01 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
0
0
Cost of Revenue
596
254
0
0
--
Gross Profit
-596
-254
0
0
--
Operating Expense
15,647
18,442
47,468
30,383
24,537
Operating Income
-16,243
-18,696
-47,468
-30,383
-24,537
Net Non Operating Interest Income Expense
-2,569
-2,522
-1,428
-2,361
-5,553
Other Income Expense
-3,500
-3,316
11,138
-11,389
-60,769
Pretax Income
-22,312
-24,534
-37,758
-44,133
-90,859
Tax Provision
252
240
613
301
705
Net Income Common Stockholders
-22,564
-24,774
-38,371
-44,434
-91,564
Diluted NI Available to Com Stockholders
-22,564
-24,774
-38,371
-44,434
-91,564
Basic EPS
-0.94
-1.26
-2.73
-3.35
-7.74
Diluted EPS
-0.94
-1.26
-2.73
-3.35
-7.74
Basic Average Shares
24,355.9940
19,699.2600
14,059.8620
13,272.6580
11,813.3150
Diluted Average Shares
24,355.9940
19,699.2600
14,059.8620
13,272.6580
11,813.3150
Total Operating Income as Reported
-16,243
-18,696
-47,468
-30,383
-24,537
Total Expenses
16,243
18,696
47,468
30,383
24,537
Net Income from Continuing & Discontinued Operation
-22,564
-24,774
-38,371
-44,434
-91,564
Normalized Income
-19,561
-21,913.6250
-48,045
-49,209.7500
-38,220.5000
Interest Expense
2,569
2,522
1,428
2,361
5,553
Net Interest Income
-2,569
-2,522
-1,428
-2,361
-5,553
EBIT
-19,743
-22,012
-36,330
-41,772
-85,306
EBITDA
-19,117
-21,728
-34,580
-39,972
-83,202
Reconciled Cost of Revenue
596
254
0
0
--
Reconciled Depreciation
626
284
1,750
1,800
2,104
Net Income from Continuing Operation Net Minority Interest
-22,564
-24,774
-38,371
-44,434
-91,564
Total Unusual Items Excluding Goodwill
-3,432
-3,269
11,056
5,458
-60,964
Total Unusual Items
-3,432
-3,269
11,056
5,458
-60,964
Normalized EBITDA
-15,685
-18,459
-45,636
-45,430
-22,238
Tax Rate for Calcs
0.0001
0.0001
0.0001
0.0001
0.0001
Tax Effect of Unusual Items
-429
-408.6250
1,382
682.2500
-7,620.5000
12/31/2021 - 5/25/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

LPCN Lipocine Inc.
3.2000
0.00%
 
SLS SELLAS Life Sciences Group, Inc.
1.6000
-2.44%
 
MIST Milestone Pharmaceuticals Inc.
1.6500
-2.37%
 
SPRO Spero Therapeutics, Inc.
2.6600
+0.76%
 
PALI Palisade Bio, Inc.
0.7175
-2.38%
 
RVPH Reviva Pharmaceuticals Holdings, Inc.
0.8145
-0.13%
 
ARTL Artelo Biosciences, Inc.
1.1006
+2.86%
 
CERO CERo Therapeutics Holdings, Inc.
0.4500
-4.05%
 
TOVX Theriva Biologics, Inc.
0.4580
-2.55%
 
CDT Conduit Pharmaceuticals Inc.
2.6800
-17.03%